免疫检查点抑制剂在复发或转移性头颈部鳞状细胞癌治疗中的进展  

Advances in immune checkpoint inhibitors in the treatment of recurrent or metastatic head and neck squamous cell carcinoma

作　　者：陈欣祎 翁一鸣[1] 魏家燕 王劲松[1] 彭敏[1] Chen Xinyi;Weng Yiming;Wei Jiayan;Wang Jinsong;Peng Min(Cancer Center,Renmin Hospital of Wuhan University,Wuhan 430060,China)

机构地区：[1]武汉大学人民医院肿瘤中心,武汉430060

出　　处：《国际肿瘤学杂志》2023年第9期553-557,共5页Journal of International Oncology

摘　　要：随着对肿瘤微环境与免疫治疗间复杂相互作用的认识,免疫检查点在头颈部鳞状细胞癌(HNSCC)治疗中的作用越来越受到关注。以程序性死亡蛋白-1(PD-1)/程序性死亡蛋白配体-1(PD-L1)、细胞毒性T淋巴细胞相关蛋白-4(CTLA-4)、T细胞免疫球蛋白黏蛋白分子-3(TIM-3)为靶点的免疫检查点抑制剂,如帕博利珠单抗、度伐利尤单抗、特瑞普利单抗、伊匹木单抗、LY3321367等,可作为单一疗法和联合疗法应用于复发或转移性HNSCC的治疗。进一步研究免疫检查点抑制剂在临床治疗中的疗效与安全性,有望为复发或转移性HNSCC患者的治疗提供更有效的策略。With the increasing understanding of the complex interaction between the tumor microenvironment and immune therapy,the role of immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinoma(HNSCC)has gained significant attention.Immune checkpoint inhibitors targeting programmed death-1(PD-1)and programmed death-ligand 1(PD-L1),cytotoxic T-lymphocyteassociated protein-4(CTLA-4),and T cell immunoglobulin domain and mucin domain-3(TIM-3),such as pembrolizumab,durvalumab,tremelimumab,ipilimumab,and LY3321367,have been applied in numerous clinical trials as monotherapies and combination therapies for the treatment of recurrent or metastatic HNSCC.Further research into the efficacy and safety of these immune checkpoint inhibitors in clinical trials may provide more effective strategies for the treatment of patients with recurrent or metastatic HNSCC.

关 键 词：头颈部肿瘤 癌 鳞状细胞 治疗 免疫检查点抑制剂 

分 类 号：R739.91[医药卫生—肿瘤]